| 前收市價 | 29.40 |
| 開市 | 29.56 |
| 買盤 | 29.65 x 200 |
| 賣出價 | 29.74 x 100 |
| 今日波幅 | 29.30 - 30.30 |
| 52 週波幅 | 21.99 - 38.09 |
| 成交量 | |
| 平均成交量 | 393,080 |
| 市值 | 1.626B |
| Beta 值 (5 年，每月) | 0.99 |
| 市盈率 (最近 12 個月) | 1,485.50 |
| 每股盈利 (最近 12 個月) | 0.02 |
| 業績公佈日 | 2024年5月07日 - 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 40.50 |
BenzingaSupernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
On Monday, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced a regulatory update for SPN-830, an investigational apomorphine infusion device under FDA review for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease (PD). The FDA has issued a Complete Response Letter (CRL) in response to the company’s New Drug Application (NDA) for SPN-830. The CRL indicates that the review cycle for the application is complete but that the application still needs to be prepa
Insider Monkey11 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the 11 best small cap pharma stocks to invest in. If you want to skip our overview of the global pharmaceutical and healthcare industry, which is one the most unique sectors in the world, then you can check out 5 Best Small Cap Pharma Stocks to […]
Insider MonkeySupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript February 27, 2024 Supernus Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to the Supernus Pharmaceuticals’ Fourth Quarter and Full Year 2023 Financial Results Conference […]
